Trending...
- Greater Dayton Real Estate Investors Association: A Non-Profit Forum to Educate & Improve Community
- Mission 3A Establishes Healthcare Advisory Board with Addition of Industry Leaders Patrick Fisher, Kevin Cordell, and Dr. Greg Berlet
- Is Billboard Advertising Still Effective in 2025?
BEACHWOOD, Ohio, May 6, 2025 ~ Trailhead Biosystems Inc. has recently announced that it has secured $20 million in financing to further its advancements in human cell innovation. The biotechnology company, known for its expertise in differentiating induced pluripotent stem cells (iPSCs) into functional human cell types, aims to unlock new possibilities for research and cell therapy.
Led by MAK Capital with participation from additional investors, this investment comes at a crucial time for Trailhead as it looks to expand its personnel, manufacturing capabilities, and strategic partnerships. Through its proprietary High-Dimensional Design of Experiments (HD-DoE®) platform, the company is able to optimize differentiation with exceptional accuracy, providing scalable solutions for both drug discovery and regenerative medicine.
The funding will also support Trailhead's rapidly growing portfolio of iPSC-derived cells for research applications. These cells are crucial in advancing preclinical drug discovery and disease modeling. Recently, the company introduced TrailBio® Vascular Leptomeningeal Cells (VLMCs), a specialized cell type used in blood-brain barrier research. Upcoming product introductions include iPSC-derived pancreatic islets, hepatocytes, dopaminergic neurons, and hematopoietic progenitors.
More on Ohio Pen
In addition to its off-the-shelf offerings, Trailhead also offers custom cell differentiation services that allow scientists to refine existing models or develop novel cell types with precise biological fidelity. This dedication to providing highly specialized human cell models aligns with the FDA's shift towards using human-based lab models as alternatives to animal testing.
According to Jan Jensen, Ph.D., CEO/CSO and founder of Trailhead Biosystems, this investment will further advance their ability to differentiate iPSCs into precise human cell types for both drug discovery and therapeutic development. By optimizing scalable differentiation processes, the company aims to accelerate discovery and develop more predictive models while supporting the next generation of cell-based therapies.
Moreover, this funding will also strengthen Trailhead's ability to support therapeutic partners in driving innovation and scalability in cell-based therapies. Investments in infrastructure and personnel will enhance manufacturing capabilities, streamline production workflows, and deepen collaborations with leading industry partners in regenerative medicine.
With this latest investment, Trailhead Biosystems is well-positioned to continue its mission of advancing human cell innovation and driving breakthroughs in research and therapy.
Led by MAK Capital with participation from additional investors, this investment comes at a crucial time for Trailhead as it looks to expand its personnel, manufacturing capabilities, and strategic partnerships. Through its proprietary High-Dimensional Design of Experiments (HD-DoE®) platform, the company is able to optimize differentiation with exceptional accuracy, providing scalable solutions for both drug discovery and regenerative medicine.
The funding will also support Trailhead's rapidly growing portfolio of iPSC-derived cells for research applications. These cells are crucial in advancing preclinical drug discovery and disease modeling. Recently, the company introduced TrailBio® Vascular Leptomeningeal Cells (VLMCs), a specialized cell type used in blood-brain barrier research. Upcoming product introductions include iPSC-derived pancreatic islets, hepatocytes, dopaminergic neurons, and hematopoietic progenitors.
More on Ohio Pen
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- Whistleblower Seeks SEC and Shareholder Review of Cogent Communications' 2003 Acquisition of FNSI
- Sanders® Celebrates 150 Years with an Immersive NYC Experience, Food Truck Tour, and Exciting New White Chocolate Caramel Creations
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
In addition to its off-the-shelf offerings, Trailhead also offers custom cell differentiation services that allow scientists to refine existing models or develop novel cell types with precise biological fidelity. This dedication to providing highly specialized human cell models aligns with the FDA's shift towards using human-based lab models as alternatives to animal testing.
According to Jan Jensen, Ph.D., CEO/CSO and founder of Trailhead Biosystems, this investment will further advance their ability to differentiate iPSCs into precise human cell types for both drug discovery and therapeutic development. By optimizing scalable differentiation processes, the company aims to accelerate discovery and develop more predictive models while supporting the next generation of cell-based therapies.
Moreover, this funding will also strengthen Trailhead's ability to support therapeutic partners in driving innovation and scalability in cell-based therapies. Investments in infrastructure and personnel will enhance manufacturing capabilities, streamline production workflows, and deepen collaborations with leading industry partners in regenerative medicine.
With this latest investment, Trailhead Biosystems is well-positioned to continue its mission of advancing human cell innovation and driving breakthroughs in research and therapy.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- ABM for Good™ Launches First Project with Build Change
- ProfiSignal 20 Update Provides Significant Features
- ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
- Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
- Jay Tapp was named Managing Director in British Columbia
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
- Cogent Communications Faces Federal Scrutiny Over Fraudulent Acquisition and 22-Year Corporate Cover-Up
- Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
- Columbus: Clean and Safe Corridors Initiative Takes Place on Sullivant Avenue
- Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
- $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
- Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
- xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
- Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
- New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions